PYC Historical Income Statement

PYC Stock

1.22 0.06 4.69%

Historical analysis of PYC Therapeutics income statement accounts such as Total Revenue of 26.6 M, Gross Profit of 26.6 M, Other Operating Expenses of 73.6 M or Research Development of 68.1 M can show how well PYC Therapeutics performed in making a profits. Evaluating PYC Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PYC Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining PYC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PYC Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About PYC Income Statement Analysis

PYC Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PYC Therapeutics shareholders. The income statement also shows PYC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

PYC Therapeutics Income Statement Chart

At this time, PYC Therapeutics' Total Operating Expenses is comparatively stable compared to the past year. Interest Income is likely to gain to about 961.1 K in 2025, despite the fact that EBITDA is likely to grow to (32.6 M).

Cost Of Revenue Selling General Administrative Total Revenue Other Operating Expenses Research Development

Cost Of Revenue

Cost of Revenue is found on PYC Therapeutics income statement and represents the costs associated with goods and services PYC Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Revenue

Total revenue comprises all receipts PYC Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PYC Therapeutics. It is also known as PYC Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from PYC Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PYC Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	882.0K	1.1M	1.2M	1.3M
Cost Of Revenue	882.0K	1.1M	1.2M	1.5M

Depreciation And Amortization Cost Of Revenue

PYC Therapeutics income statement Correlations

	Cost Of Revenue	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Interest Income	Net Interest Income	Reconciled Depreciation	Minority Interest
Cost Of Revenue		-0.23	-0.4	-0.16	-0.28	-0.2	0.32	0.32	-0.19	0.32	-0.24	0.27	0.12	0.28	0.39	0.23	0.3	-0.16	-0.06	-0.4	0.28
Depreciation And Amortization	-0.23		0.8	0.95	0.95	0.95	-0.94	-0.94	0.94	-0.93	0.95	-0.95	-0.86	-0.94	-0.9	-0.12	-0.94	0.78	0.71	0.86	-0.94
Selling General Administrative	-0.4	0.8		0.66	0.69	0.68	-0.79	-0.78	0.63	-0.78	0.69	-0.73	-0.54	-0.72	-0.7	-0.31	-0.73	0.44	0.32	0.93	-0.85
Total Revenue	-0.16	0.95	0.66		0.99	0.98	-0.92	-0.92	0.98	-0.92	0.97	-0.96	-0.88	-0.93	-0.93	-0.07	-0.93	0.83	0.77	0.74	-0.92
Gross Profit	-0.28	0.95	0.69	0.99		0.98	-0.92	-0.92	0.97	-0.92	0.98	-0.96	-0.87	-0.94	-0.95	-0.09	-0.94	0.83	0.77	0.76	-0.92
Other Operating Expenses	-0.2	0.95	0.68	0.98	0.98		-0.91	-0.91	1.0	-0.91	1.0	-0.97	-0.89	-0.97	-0.89	-0.05	-0.97	0.89	0.83	0.72	-0.91
Operating Income	0.32	-0.94	-0.79	-0.92	-0.92	-0.91		1.0	-0.89	1.0	-0.91	0.97	0.86	0.94	0.95	0.1	0.94	-0.65	-0.55	-0.86	0.97
Ebit	0.32	-0.94	-0.78	-0.92	-0.92	-0.91	1.0		-0.9	1.0	-0.91	0.97	0.86	0.94	0.95	0.1	0.94	-0.65	-0.55	-0.85	0.97
Research Development	-0.19	0.94	0.63	0.98	0.97	1.0	-0.89	-0.9		-0.9	1.0	-0.96	-0.9	-0.97	-0.88	-0.03	-0.96	0.91	0.85	0.68	-0.89
Ebitda	0.32	-0.93	-0.78	-0.92	-0.92	-0.91	1.0	1.0	-0.9		-0.91	0.97	0.86	0.94	0.95	0.09	0.94	-0.65	-0.55	-0.85	0.97
Total Operating Expenses	-0.24	0.95	0.69	0.97	0.98	1.0	-0.91	-0.91	1.0	-0.91		-0.97	-0.89	-0.97	-0.9	-0.05	-0.97	0.89	0.83	0.72	-0.91
Income Before Tax	0.27	-0.95	-0.73	-0.96	-0.96	-0.97	0.97	0.97	-0.96	0.97	-0.97		0.9	0.99	0.94	0.08	0.99	-0.8	-0.72	-0.79	0.95
Total Other Income Expense Net	0.12	-0.86	-0.54	-0.88	-0.87	-0.89	0.86	0.86	-0.9	0.86	-0.89	0.9		0.9	0.81	0.12	0.9	-0.77	-0.73	-0.6	0.82
Net Income	0.28	-0.94	-0.72	-0.93	-0.94	-0.97	0.94	0.94	-0.97	0.94	-0.97	0.99	0.9		0.89	0.09	1.0	-0.85	-0.78	-0.75	0.92
Income Tax Expense	0.39	-0.9	-0.7	-0.93	-0.95	-0.89	0.95	0.95	-0.88	0.95	-0.9	0.94	0.81	0.89		0.08	0.89	-0.66	-0.57	-0.81	0.93
Selling And Marketing Expenses	0.23	-0.12	-0.31	-0.07	-0.09	-0.05	0.1	0.1	-0.03	0.09	-0.05	0.08	0.12	0.09	0.08		0.12	-0.01	0.01	-0.3	0.16
Net Income From Continuing Ops	0.3	-0.94	-0.73	-0.93	-0.94	-0.97	0.94	0.94	-0.96	0.94	-0.97	0.99	0.9	1.0	0.89	0.12		-0.85	-0.77	-0.76	0.92
Interest Income	-0.16	0.78	0.44	0.83	0.83	0.89	-0.65	-0.65	0.91	-0.65	0.89	-0.8	-0.77	-0.85	-0.66	-0.01	-0.85		0.98	0.46	-0.65
Net Interest Income	-0.06	0.71	0.32	0.77	0.77	0.83	-0.55	-0.55	0.85	-0.55	0.83	-0.72	-0.73	-0.78	-0.57	0.01	-0.77	0.98		0.34	-0.55
Reconciled Depreciation	-0.4	0.86	0.93	0.74	0.76	0.72	-0.86	-0.85	0.68	-0.85	0.72	-0.79	-0.6	-0.75	-0.81	-0.3	-0.76	0.46	0.34		-0.87
Minority Interest	0.28	-0.94	-0.85	-0.92	-0.92	-0.91	0.97	0.97	-0.89	0.97	-0.91	0.95	0.82	0.92	0.93	0.16	0.92	-0.65	-0.55	-0.87

Click cells to compare fundamentals

PYC Therapeutics Account Relationship Matchups

PYC Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	38.8K	32.6K	27.3K	49.2K	56.6K	59.4K
Cost Of Revenue	622.4K	839.5K	882.0K	1.1M	1.2M	1.5M
Depreciation And Amortization	622.4K	839.5K	882.0K	1.1M	1.2M	1.3M
Selling General Administrative	7.8M	6.3M	4.1M	4.5M	5.2M	5.4M
Total Revenue	3.1M	16.0M	15.8M	22.1M	25.4M	26.6M
Gross Profit	2.5M	15.2M	14.9M	22.1M	25.4M	26.6M
Other Operating Expenses	21.8M	30.2M	39.2M	60.9M	70.1M	73.6M
Operating Income	(21.8M)	(30.2M)	(39.2M)	(38.9M)	(35.0M)	(33.2M)
Ebit	(21.7M)	(30.2M)	(39.1M)	(39.2M)	(35.3M)	(33.5M)
Research Development	14.0M	24.0M	35.1M	56.4M	64.9M	68.1M
Ebitda	(21.0M)	(29.4M)	(38.3M)	(38.1M)	(34.3M)	(32.6M)
Total Operating Expenses	21.2M	29.4M	38.3M	60.9M	70.1M	73.6M
Income Before Tax	(21.7M)	(30.3M)	(39.2M)	(55.7M)	(50.1M)	(47.6M)
Total Other Income Expense Net	(2.9M)	(8.2K)	(15.7M)	(16.8M)	(15.1M)	(14.4M)
Net Income	(17.8M)	(13.9M)	(22.8M)	(37.7M)	(34.0M)	(32.3M)
Income Tax Expense	(3.1M)	(16.0M)	(15.8M)	(17.6M)	(15.8M)	(15.0M)
Selling And Marketing Expenses	541.5K	622.4K	960.4K	956.1K	1.1M	1.1M
Net Income From Continuing Ops	(18.6M)	(14.3M)	(23.4M)	(38.1M)	(34.3M)	(32.6M)
Net Income Applicable To Common Shares	(6.8M)	(17.8M)	(13.9M)	(22.8M)	(20.5M)	(19.5M)
Interest Income	108.5K	24.4K	81.8K	796.0K	915.4K	961.1K
Net Interest Income	69.7K	(8.2K)	54.6K	746.8K	858.8K	901.7K
Reconciled Depreciation	622.4K	839.5K	551.2K	600.9K	691.0K	471.4K
Minority Interest	880.3K	430.8K	567.5K	385.0K	346.5K	329.2K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PYC Stock Analysis

When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC